Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

Final draft guidance

Final draft guidance (PDF 222 KB)

Public committee slides (PDF 838 KB)

Committee papers (PDF 1.48 MB)

Draft guidance

Draft guidance (downloadable version) (PDF 246 KB)

Committee papers (PDF 8.85 MB)

Public committee slides (PowerPoint 1.97 MB)

Equality impact assessment (downloadable version) (PDF 127 KB)

Committee meeting

Final scope (PDF 124 KB)

Final stakeholder list (PDF 154 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 211 KB)

Draft scope post referral (PDF 178 KB)